Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas.
A multimodality approach including operation and isolated lung perfusion with platinum was used in six patients with lung metastases from soft tissue sarcomas. Staged thoracotomies were used in two patients with bilateral lesions. The inclusion criteria generally applied for surgical excision were adopted in this study. The pulmonary artery and a portion of the left atrium were isolated from systemic circulation and cannulated. The cannulas were then connected to a perfusion circuit and normothermic isolated lung perfusion was done for 60 minutes. The lung was then flushed and metastasectomy was done. Serial blood (systemic and pulmonary), tissue (normal lung and tumor), and urine samples were obtained for platinum content measurement by flameless atomic absorption spectroscopy. Lung damage was assessed by light and electron microscopy examination and by serial respiratory tests. Isolated lung perfusion was accomplished in all patients without any death, operative complication, or systemic toxicity. After operation, interstitial and alveolar edema developed in two patients (48 hours after treatment), necessitating respiratory support in one case. Total platinum concentrations in pulmonary plasma were about 43 times greater than those in systemic plasma. No differences in platinum concentrations between normal lung and metastatic tissue were found. Thus the proposed isolated lung perfusion technique is feasible and safe enough to be offered as a valid model to study combined chemosurgical approaches in the treatment of lung metastases.
Ratto
G B
GB
Department of Patologia Chirurgica, University of Genoa, Italy.
Toma
S
S
Civalleri
D
D
Passerone
G C
GC
Esposito
M
M
Zaccheo
D
D
Canepa
M
M
Romano
P
P
Palumbo
R
R
De Cian
F
F
Scarano
F
F
Vannozzi
M
M
Spessa
E
E
Fantino
G
G
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine; D006328:Cardiac Catheterization; D002407:Catheterization, Swan-Ganz; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D006325:Heart Atria; D006801:Humans; D008168:Lung / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary* / Q000601:surgery; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D011013:Pneumonectomy / Q000009:adverse effects; D011183:Postoperative Complications; D011651:Pulmonary Artery; D011654:Pulmonary Edema / Q000209:etiology; D012129:Respiratory Function Tests; D012449:Safety; D012509:Sarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary* / Q000601:surgery; D013054:Spectrophotometry, Atomic; D013908:Thoracotomy
D000970:Antineoplastic Agents; D002945:Cisplatin